Moreover, several studies have revealed the potential roles of incretin-based therapies, including DPP-4 inhibitors and GLP-1 receptor agonists, in the treatment of NAFLD [18,19]. This evidence concerns the gene DPP4 and metabolic dysfunction-associated steatotic liver disease.